Introduction
============

Epidemiology
------------

Malaria in pregnancy (MiP) is a major public health problem in endemic countries. There is a wealth of evidence showing that the risk of malaria (both infection and clinical disease) is higher in pregnant than in non-pregnant women, possibly due to the immunological, hormonal changes or other factors occurring during pregnancy. Most of the available evidence is on *Plasmodium falciparum* and *P. vivax*, though for the latter, there is much less information than for *P. falciparum*, while little is known on *P. ovale* and *P. malariae*, the other two human malaria species. This review will focus on *P.falciparum* and *P. vivax*, with the objective of providing an update on the recently acquired knowledge (since the year 2000).

Burden
------

Where transmission is stable and relatively high, mainly in sub-Saharan Africa, adults have acquired immunity against malaria, including pregnant women who, despite the immune tolerance occurring during pregnancy, are able to control but not clear malaria infections. Therefore, in this high risk group, asymptomatic infections are common while clinical malaria is relatively rare. A recent review of studies, carried out in sub-Saharan Africa between 2000 and 2011, reports that malaria prevalence in pregnant women attending antenatal clinics was 29.5% (95%CI: 22.4--36.5) in East and Southern Africa, and 35.1% (95%CI: 28.2--41.9) in West and Central Africa, while the prevalence of placenta malaria was 26.5% (95%CI: 16.7--36.4) in East and Southern Africa, and 38% (95%CI: 28.4--47.6) in West and Central Africa.[@b1-mjhid-5-1-e2013010] More recently (studies published since 2008), the reported malaria prevalence (by microscopy unless specified otherwise) was lower, reflecting the recent decrease in malaria transmission observed in several African countries[@b2-mjhid-5-1-e2013010]--[@b11-mjhid-5-1-e2013010] ([Table 1](#t1-mjhid-5-1-e2013010){ref-type="table"}). Most of the prevalence estimates were done by microscopy and they would probably be higher if more sensitive methods like PCR[@b12-mjhid-5-1-e2013010] or placental histology[@b13-mjhid-5-1-e2013010] were used. In addition, blood samples were collected at different times during pregnancy, increasing the difficulty of comparing different estimates.

In areas of low, unstable malaria transmission, mainly Asia-Pacific region and South America, pregnant women have a lower acquired immunity and malaria infections are more likely to evolve towards clinical disease. The number of pregnancies occurring in these areas has been estimated at 70.5 million in 2007.[@b14-mjhid-5-1-e2013010] In the Asia-Pacific region, the median proportion of women with peripheral infection has been estimated at 15.3% and that of placenta malaria at 11%.[@b15-mjhid-5-1-e2013010] For South and Central America, less data on the burden of malaria in pregnancy is available ([Table 2](#t2-mjhid-5-1-e2013010){ref-type="table"}). In Peru, the cumulative incidence of clinical malaria in pregnant women for the period January--August 2004 and 2005 was 43.1% as compared to 31.6% in non-pregnant women.[@b16-mjhid-5-1-e2013010] This study also suggested that subclinical malaria infections may occur frequently among pregnant women in this region, despite the relatively low transmission, and that passive surveillance, i.e. data collection at health facilities, may underestimate the actual burden of MiP. In Colombia, the prevalence of malaria among parturient women attending the local hospital was 13% when determined by microscopy and 32% by PCR.[@b17-mjhid-5-1-e2013010] In the same study, the prevalence of placenta malaria was 9% by microscopy and 26% by PCR, while 2% and 13% of cord blood samples were positive by microscopy and PCR, respectively.

Risk Factors
------------

Maternal factors associated with the risk of malaria in pregnancy include maternal age, parity and gestational age. It is well established that younger women (primigravidae and multigravidae), particularly adolescents, are at higher risk of malaria infection than older women,[@b18-mjhid-5-1-e2013010]--[@b20-mjhid-5-1-e2013010] and this is independent of parity.[@b20-mjhid-5-1-e2013010]--[@b22-mjhid-5-1-e2013010] Parity also affects the risk of malaria as primigravidae are at higher risk than multigravidae,[@b18-mjhid-5-1-e2013010]--[@b20-mjhid-5-1-e2013010], [@b23-mjhid-5-1-e2013010]--[@b24-mjhid-5-1-e2013010] though less in low transmission settings,[@b15-mjhid-5-1-e2013010] while in epidemic areas, the risk is not affected by parity.[@b25-mjhid-5-1-e2013010] Most of the available data on malaria relate to the second and third trimesters.[@b12-mjhid-5-1-e2013010], [@b19-mjhid-5-1-e2013010], [@b26-mjhid-5-1-e2013010]--[@b27-mjhid-5-1-e2013010] The peak of malaria prevalence seems to occur during the second trimester.[@b28-mjhid-5-1-e2013010] Studies on malaria burden in the first trimester of pregnancy are scarce, but it is believed that the rates are similar to that of the second trimester. However, considering the difficulty of collecting this information (pregnant women start to attend the antenatal clinic after the first trimester), and of determining the gestational age with accuracy, it is unclear whether the risk starts to increase towards the end of the first trimester. Indeed, in Burkina Faso, malaria prevalence was higher during the first as compared to the second and third trimesters.[@b29-mjhid-5-1-e2013010]

Effects of Malaria Infection
----------------------------

The effect of malaria infection during pregnancy will depend on the degree of acquired immunity, which in turn depends on the intensity of transmission.

### Maternal effects

Where transmission is stable, such as in most of sub-Saharan Africa, most infections are asymptomatic but increase substantially the risk of anaemia.[@b19-mjhid-5-1-e2013010],[@b26-mjhid-5-1-e2013010],[@b30-mjhid-5-1-e2013010]--[@b31-mjhid-5-1-e2013010] This occurs over a background of physiological anaemia of pregnancy due to increased blood volume. Both symptomatic and asymptomatic infections can cause anaemia. Severe anaemia is more often observed in stable transmission settings,[@b32-mjhid-5-1-e2013010]--[@b34-mjhid-5-1-e2013010] and more in primigravidae than in multigravidae.[@b35-mjhid-5-1-e2013010]--[@b36-mjhid-5-1-e2013010] Malaria infections in the first or second trimester of pregnancy increase the risk of anaemia,[@b24-mjhid-5-1-e2013010],[@b30-mjhid-5-1-e2013010] though one study reported an increased risk also for infections occurring in the third trimester.[@b30-mjhid-5-1-e2013010] Preventing malaria infection by intermittent preventive treatment during pregnancy (IPTp) reduces the risk of anaemia.[@b27-mjhid-5-1-e2013010],[@b37-mjhid-5-1-e2013010]--[@b38-mjhid-5-1-e2013010]

Where malaria transmission is unstable, malaria can cause maternal anaemia,[@b18-mjhid-5-1-e2013010],[@b35-mjhid-5-1-e2013010],[@b39-mjhid-5-1-e2013010]--[@b40-mjhid-5-1-e2013010] more in primigravidae than in multigravidae and for falciparum infections more than for vivax infections.[@b18-mjhid-5-1-e2013010],[@b35-mjhid-5-1-e2013010] Nevertheless, severe anaemia is less common in these settings.[@b39-mjhid-5-1-e2013010],[@b41-mjhid-5-1-e2013010]

In places where malaria transmission is stable, little is known on the importance of malaria infection as a cause of miscarriage. Where malaria transmission is unstable, malaria as a cause of miscarriage seems more common, as the majority of infections evolve towards a clinical attack with fever, which may by itself determine miscarriage. Indeed, non malarial fevers also independently increase the risk of miscarriage.[@b18-mjhid-5-1-e2013010],[@b42-mjhid-5-1-e2013010] Nevertheless, asymptomatic infections, i.e. slide confirmed malaria with no history of fever in the previous 48 hours and temperature \<37.5 °C, was also associated with miscarriage.[@b7-mjhid-5-1-e2013010]

Maternal mortality associated to malaria is probably under-reported. Malaria was an important cause of maternal death in some studies,[@b43-mjhid-5-1-e2013010]--[@b45-mjhid-5-1-e2013010] while in others it was not as frequent.[@b46-mjhid-5-1-e2013010] The substantial reduction in maternal mortality observed in Thailand after the implementation of early detection and treatment of malaria suggests that malaria is an important contributor to maternal mortality.[@b47-mjhid-5-1-e2013010] When not a direct cause of death (severe malaria),[@b47-mjhid-5-1-e2013010] malaria in pregnancy is often reported as co-morbidity, e.g. with eclampsia, in conditions associated with maternal mortality.[@b44-mjhid-5-1-e2013010],[@b48-mjhid-5-1-e2013010]

### Perinatal effects

Malaria increases the risk of low birth weight (LBW),[@b19-mjhid-5-1-e2013010],[@b23-mjhid-5-1-e2013010],[@b30-mjhid-5-1-e2013010],[@b49-mjhid-5-1-e2013010]--[@b51-mjhid-5-1-e2013010] particularly in primigravidae, and this risk seems to be higher for infections in first or second trimester,[@b23-mjhid-5-1-e2013010]--[@b24-mjhid-5-1-e2013010],[@b30-mjhid-5-1-e2013010],[@b49-mjhid-5-1-e2013010] though in one study this was true also for infections occurring late in pregnancy.[@b49-mjhid-5-1-e2013010] In high malaria transmission settings, such an effect is due to intrauterine growth retardation (IUGR) rather than pre-term delivery, as most infections are asymptomatic. A meta-analysis of 32 cross-sectional data in Africa, showed malaria prevention in pregnancy is associated with 21% (95% CI= 14--27) reduction in LBW.[@b52-mjhid-5-1-e2013010]

In unstable transmission settings, preterm deliveries, still births and neonatal deaths have been associated with malaria.[@b18-mjhid-5-1-e2013010]*P.vivax* infections are also associated with LBW, and this effect appears to be similar in all pregnancies. In women with a single infection of *P.vivax* or *P.falciparum* detected and treated in the first trimester, no significant effect on gestation or birth weight was observed compared to women who also attended in the first trimester but who never had malaria detected in pregnancy.[@b42-mjhid-5-1-e2013010]

### New born and infant effects

Fewer studies on malaria in pregnant women have evaluated infant outcomes. Congenital malaria can occur in the neonatal period and can contribute to infant morbidity and mortality.[@b53-mjhid-5-1-e2013010] Placenta malaria, especially active infection, has been linked to neonatal and infant mortality.[@b53-mjhid-5-1-e2013010] A recent study in The Gambia has showed that malaria infection during pregnancy influences infant's growth, independently of LBW.[@b54-mjhid-5-1-e2013010] It also increases the risk of infant's death and perinatal mortality, by causing LBW.[@b39-mjhid-5-1-e2013010],[@b53-mjhid-5-1-e2013010],[@b55-mjhid-5-1-e2013010] This is confirmed by the reduction neonatal mortality, up to 60%, observed after the implementation of preventive interventions targeted to pregnant women, e.g. intermittent preventive treatment.[@b56-mjhid-5-1-e2013010]--[@b57-mjhid-5-1-e2013010] In primi- and secundigravidae, malaria prevention with IPTp or insecticide-treated bed nets was significantly associated with a 18% decreased risk of neonatal mortality.[@b52-mjhid-5-1-e2013010]

### Later childhood, adolescence and adulthood effects

The long term effects of malaria in pregnancy have not been studied. However, malaria causes IUGR leading to LBW, which may be related to diseases occurring during adulthood, including some cancers and the metabolic syndrome.[@b58-mjhid-5-1-e2013010]

Pathophysiology
===============

Pregnant women are at higher risk of contracting malaria than non-pregnant women. This increased susceptibility can be explained by the immunological changes induced by pregnancy, by hormonal factors,[@b59-mjhid-5-1-e2013010] and by the higher attractiveness of pregnant women to mosquitoes.[@b60-mjhid-5-1-e2013010]--[@b61-mjhid-5-1-e2013010] In addition, *P. falciparum* -infected erythrocytes in pregnant women bind to specific receptors, i.e. chondroitin sulphate A (CSA), and sequester in the placenta.[@b62-mjhid-5-1-e2013010]--[@b63-mjhid-5-1-e2013010] They rarely bind to the other two commonly described receptors in non-pregnant individuals, i.e. CD36 and the intracellular adhesion molecule (ICAM-1). In pregnancy, the parasite antigens expressed on infected erythrocytes are collectively known as variant surface antigen-pregnancy associated malaria (VSA~PAM~). They are different from those expressed in non-pregnant individuals and in stable transmission settings are not recognised by the immune system, explaining the higher risk in primigravidae.[@b64-mjhid-5-1-e2013010] The binding of the variant surface antigen (VAR2CSA) with chondroitin sulphate A has been implicated in the pathology of falciparum malaria in pregnancy.[@b65-mjhid-5-1-e2013010]--[@b68-mjhid-5-1-e2013010] The VAR2CSA belongs to the family of the erythrocyte membrane protein (PfEMP1), is encoded by the var2csa gene and its expression has been described in pregnant women with falciparum malaria.[@b69-mjhid-5-1-e2013010] Levels of anti-VAR2CSA specific IgGs increase with parity, cannot be found in men and are associated with a favourable pregnancy outcome [@b64-mjhid-5-1-e2013010]--[@b66-mjhid-5-1-e2013010] so that the malaria risk decreases with increasing parity. Besides the antibody responses to VSA~PAM~, cytokine responses such as Th1, Th2, interleukins, TNF and regulators, IFN gamma,[@b70-mjhid-5-1-e2013010]--[@b72-mjhid-5-1-e2013010] and monocytes[@b73-mjhid-5-1-e2013010] have been observed in pregnant women with malaria. Rosetting, a phenomenon consisting of parasite-free erythrocytes surrounding parasite-infected erythrocytes and commonly observed in non-pregnant individuals, has been implicated in the pathogenesis of severe malaria[@b74-mjhid-5-1-e2013010]--[@b75-mjhid-5-1-e2013010] but is uncommon in pregnant women with falciparum malaria.[@b76-mjhid-5-1-e2013010]

The sequestration of *P. vivax* in the placenta, though until recently thought not to occur, has been described,[@b77-mjhid-5-1-e2013010]--[@b78-mjhid-5-1-e2013010] with the involvement of ICAM-1 and CSA as receptors.

The effects of hormonal changes on pregnancy associated malaria have been described in few studies and are subject to debate. Increased cortisol levels have been associated with increased risk of malaria in pregnant women.[@b79-mjhid-5-1-e2013010]

The increased attractiveness of pregnant women to mosquitoes may be explained by physiological and behavioural changes occurring during pregnancy. Physiological changes include increased exhaled breath and increased abdominal temperature that may render pregnant women more easily detectable by mosquitoes. Behavioural changes are represented by the fact that pregnant women urinate twice as frequently as non-pregnant women, resulting in an increased exposure to mosquito bites at night because they have to leave the protection of their bed nets.[@b60-mjhid-5-1-e2013010]--[@b61-mjhid-5-1-e2013010]

Malaria-associated placental changes have been described for stable[@b72-mjhid-5-1-e2013010],[@b80-mjhid-5-1-e2013010] and unstable transmission settings.[@b73-mjhid-5-1-e2013010],[@b81-mjhid-5-1-e2013010] They include presence of parasites, inflammatory changes and hemozoin (pigment) deposition. Placental changes have been characterised into four levels, i.e. acute (parasites present, malaria pigment absent), chronic (parasites and malaria pigment present), past infection (no parasite but pigment present) and no infection (both parasites and malaria pigment absent).[@b82-mjhid-5-1-e2013010] Recently, a 2-parameter grading system, distinguishing between inflammation and pigment deposition, has been proposed as it correlates with pregnancy outcomes, in both a stable transmission setting in Tanzania, and an unstable setting in Thailand.[@b73-mjhid-5-1-e2013010]

It is unclear what the mechanism at the basis of malaria-related preterm delivery is, though fever, anaemia, and high levels of TNF alpha or interleukin 10 have been identified as important risk factors.[@b18-mjhid-5-1-e2013010],[@b83-mjhid-5-1-e2013010]--[@b84-mjhid-5-1-e2013010]

LBW due to IUGR is associated with maternal anaemia,[@b83-mjhid-5-1-e2013010],[@b85-mjhid-5-1-e2013010] and elevated levels of cytokines.[@b70-mjhid-5-1-e2013010] Although the exact mechanism has not been elucidated, it appears to be due to chronic infections that cause reduced foetal circulation and placental insufficiency.[@b86-mjhid-5-1-e2013010] Placental endocrine changes related to falciparum infection have been suggested as another possible mechanism leading to IUGR.[@b87-mjhid-5-1-e2013010]

*P.vivax* is different from *P. falciparum* as it infects immature erythrocytes (reticulocytes), limiting the parasite densities. In addition, it can relapse during pregnancy due to the activation of liver hypnozoites. Vivax parasites do not frequently express variant surface antigens, at the basis of placenta sequestration, so that this does not occur frequently.[@b81-mjhid-5-1-e2013010] Therefore, *P. vivax* probably affects birth weight, and increases the risk of miscarriage and preterm birth through a systemic rather than a local effect. Nevertheless, the mechanisms at the basis of these observations are not completely understood.

Clinical Presentation
=====================

Diagnosis
---------

The diagnosis of malaria in pregnancy is essential to prevent its deleterious effects to the mother and the foetus. Unfortunately, the clinical signs of malaria in pregnant women are usually non specific, and where transmission is stable, most infections are asymptomatic. Therefore, suspected malaria cases should be confirmed by parasitological diagnosis,[@b88-mjhid-5-1-e2013010] usually by microscopy and/or rapid diagnostic tests. Nevertheless, other methods such as PCR and placental histology can be also used, though the latter can be done only after delivery so that it cannot be used for the management of infections occurring during pregnancy.

Microscopy is one of the most widely used methods for diagnosing malaria, including during pregnancy. It has some advantages such as the possibility of determining the parasite density and species. However, its major disadvantage, besides the need of a regular power supply, is its sensitivity, which cannot go below 10--15 parasites per μl. Therefore, a substantial proportion of infected pregnant women would not be detected because of extremely low parasite densities or of parasites sequestered in the placenta, though both conditions have deleterious effects on the mother's and her offspring's health.

Several studies have investigated the use of microscopy for the diagnosis of MiP in stable malaria transmission settings in Africa.[@b89-mjhid-5-1-e2013010]--[@b91-mjhid-5-1-e2013010] When taking placenta histology as the reference test, the sensitivity of peripheral blood microscopy for \_*P. falciparum* infections (4 studies) was 60% (95% CI=50--69) and that of placental microscopy 45% (95% CI=34--56).[@b13-mjhid-5-1-e2013010]

In settings with unstable malaria transmission, there are few studies on the sensitivity of microscopy on peripheral blood collected during pregnancy.[@b13-mjhid-5-1-e2013010]

Rapid diagnostic tests (RDT), detecting circulating malaria antigens, can also be used. Generally, the sensitivity of RDTs for the diagnosis of malaria in pregnancy is lower than that of microscopy. However, the time needed for the diagnosis is shorter than for microscopy and the training required for their use is minimal. Although RDT can detect malaria antigens, they cannot estimate the parasite density. The sensitivity of RDT on peripheral blood using peripheral microscopy as a reference test is estimated at 81% (95% CI= 55--95), and the sensitivity of RDT on placental blood was 81% (95% CI= 62--92) using placental microscopy as the reference.[@b13-mjhid-5-1-e2013010]

PCR, which detects parasite DNA, can also be used for the diagnosis of malaria infection but is not readily available in health facilities. In stable transmission settings, the sensitivity of PCR was \>80% when using microscopy as the reference.[@b13-mjhid-5-1-e2013010] PCR sensitivity has not been estimated against placental histology as reference test.

Severe malaria
--------------

Severe malaria in pregnancy is more common in unstable transmission settings because of the lower immunity pregnant women have. Generally, women in the second and third trimesters of pregnancy are at a higher risk of developing severe malaria compared to non-pregnant adults. In low transmission settings, severe malaria in pregnancy is usually associated with pulmonary oedema, hypoglycaemia and severe anaemia. Mortality in pregnant women with severe malaria and treated with either artesunate and quinine varied between 9% and 12%.[@b92-mjhid-5-1-e2013010]

Prevention and Treatment
========================

Prevention
----------

The most widely used interventions to prevent malaria in pregnancy are insecticide-treated bed nets (ITN), including Long-Lasting Insecticidal Nets (LLINs), and intermittent preventive treatment in pregnancy (IPTp).

While ITNs have shown a substantial reduction in malaria morbidity and mortality in children,[@b93-mjhid-5-1-e2013010]--[@b94-mjhid-5-1-e2013010],[@b95-mjhid-5-1-e2013010],[@b96-mjhid-5-1-e2013010] in pregnant women, it has been associated with a decrease in maternal parasitaemia (38%), anaemia (41%) and LBW (28%),[@b97-mjhid-5-1-e2013010] and 47% reduction in maternal anaemia.[@b98-mjhid-5-1-e2013010] In one study, there was no evidence of a reduction in anaemia and parasitaemia.[@b99-mjhid-5-1-e2013010]

IPTp is the administration of therapeutic doses of an antimalarial, currently sulfadoxine-pyrimethamine (SP), at least twice during pregnancy, in the second and third trimester, irrespective of the presence of a malaria infection. The WHO recommends its use and many sub-Saharan African countries have included it in their malaria control program. In stable transmission settings, many trials have shown that SP given as IPTp is efficacious in preventing the adverse consequences of malaria during pregnancy ([Table 3](#t3-mjhid-5-1-e2013010){ref-type="table"}).[@b100-mjhid-5-1-e2013010]--[@b104-mjhid-5-1-e2013010] However, SP resistance represents a major threat. A study in Benin has showed that, despite the presence of molecular markers of resistance, SP remained efficacious.[@b105-mjhid-5-1-e2013010] This has been confirmed by a review reporting that IPTp with SP is effective up to a certain level of SP resistance.[@b106-mjhid-5-1-e2013010] Nevertheless, finding an alternative to SP for IPTp is important. Adding amodiaquine to SP was efficacious but not better than SP alone.[@b107-mjhid-5-1-e2013010] Mefloquine (MQ), thanks to its long elimination half-life, could be a good alternative to SP as it would provide a long post-treatment prophylactic period. Indeed, a trial in Benin showed that for IPTp MQ was as good as SP in preventing LBW. MQ was more efficacious than SP in preventing placental malaria, clinical malaria and maternal anaemia at delivery. However, MQ was less well tolerated than SP, potentially compromising its large scale use as IPTp.[@b108-mjhid-5-1-e2013010]--[@b109-mjhid-5-1-e2013010]

There is no evidence that one of the methods is better than the other[@b110-mjhid-5-1-e2013010] and the combined use appears to be better than individual use.

A different approach is systematic screening for malaria infections at regular intervals and treatment of the positive women, which may be more appropriate in settings where malaria transmission is low and the risk of infection between antenatal visits is also low. It has already be shown to have similar protective efficacy than IPTp but additional trials for a more thorough evaluation of this intervention are probably needed.[@b26-mjhid-5-1-e2013010] Due to drug resistant malaria, it has been the only form of malaria control on the Thai-Burmese border for more than 20 years, impacting significantly on maternal mortality rates.[@b47-mjhid-5-1-e2013010]

In future, vaccines specifically designed to prevent MiP may become available; VAR2CSA, in the early stages of development, seems the most promising candidate.[@b111-mjhid-5-1-e2013010]--[@b116-mjhid-5-1-e2013010] However, there are still several uncertainties, including the number of antigenic variants to be combined for an optimal response, the timing of the vaccine, e.g. during pregnancy or at puberty, whether only first pregnancies should be targeted, and the length of follow up for children born to vaccinated mothers.[@b111-mjhid-5-1-e2013010]--[@b112-mjhid-5-1-e2013010],[@b117-mjhid-5-1-e2013010]

Treatment
---------

It is recommended that pregnant women with malaria are treated after parasitological confirmation of the diagnosis, reducing the unnecessary exposure to antimalarials of both the mother and the foetus.

### First trimester

Clinical trials on the safety and efficacy of antimalarials in pregnancy usually exclude women in the first trimester of pregnancy so that the evidence is based on observational studies ([Table 4](#t4-mjhid-5-1-e2013010){ref-type="table"}). Artemisinin derivatives were relatively safe (n=1937) in the first trimester of pregnancy[@b42-mjhid-5-1-e2013010],[@b118-mjhid-5-1-e2013010]--[@b119-mjhid-5-1-e2013010] and the cumulative failure rate reported in only one study was 6.6% across all trimesters (n=461).[@b118-mjhid-5-1-e2013010] No major adverse event was observed in 377 women with known pregnancy outcome and exposed to artemisinins in the first trimester.[@b42-mjhid-5-1-e2013010],[@b119-mjhid-5-1-e2013010]--[@b121-mjhid-5-1-e2013010] However, only 1 study[@b120-mjhid-5-1-e2013010] out of 4, was a randomised controlled trial though the treatment was given during a mass campaign and the exposure was thus inadvertent; the birth weight of newborns delivered by women exposed to artesunate during the first trimester was similar to that of the other pregnant women. According to recommendations,[@b88-mjhid-5-1-e2013010] chloroquine, quinine, clindamycin and proguanil can be considered safe in the first trimester.

In case of uncomplicated malaria in the first trimester, a combination of quinine + clindamycin for 7 days is recommended.

In case of severe malaria, parenteral antimalarials are recommended.[@b88-mjhid-5-1-e2013010] In the first trimester, the risk of hypoglycaemia is lower and the uncertainties on the safety of the artemisinins derivatives are greater. Nevertheless, considering that treatment should not be delayed and that artesunate reduces the risk of death, both artesunate and quinine (parenteral) may be considered as options. Treatment should be started immediately with the most readily available drug.[@b90-mjhid-5-1-e2013010]

### Second and third trimesters

There is more experience on the use of artemisinin derivatives in the second and third trimesters of pregnancy. Evidence is available from both trials[@b122-mjhid-5-1-e2013010]--[@b127-mjhid-5-1-e2013010] and observational studies[@b128-mjhid-5-1-e2013010]--[@b131-mjhid-5-1-e2013010] involving pregnant women ([Table 4](#t4-mjhid-5-1-e2013010){ref-type="table"}). Data available indicate that ACTs are relatively safe for the foetus when taken after the first trimester of pregnancy. A recent review of treatment studies carried out in pregnant women from 1998--2009, reported a parasitological failure \>5% in 3 out of 11 trials.[@b132-mjhid-5-1-e2013010] In the second trimester, ACTs that are known to be effective in the area, or 7 days artesunate+ clindamycin, or 7 days quinine+ clindamycin are recommended for uncomplicated malaria.[@b88-mjhid-5-1-e2013010] In case of severe malaria, parenteral artesunate is preferable because it saves the life of the mother. Several studies have shown that the kinetics of artemisinins derivatives, most specifically of the active metabolite dihydroartemisinin, is modified during pregnancy.[@b133-mjhid-5-1-e2013010]--[@b134-mjhid-5-1-e2013010]

Amodiaquine (AQ) has been shown to be efficacious in pregnant women with falciparum malaria in Ghana and Tanzania.[@b122-mjhid-5-1-e2013010],[@b125-mjhid-5-1-e2013010] Day 28 parasitological failure rates were 3% for AQ monotherapy,[@b122-mjhid-5-1-e2013010] 0--1% for the combination AQ+SP,[@b122-mjhid-5-1-e2013010],[@b125-mjhid-5-1-e2013010] and 4.5% for the combination AS+AQ.[@b125-mjhid-5-1-e2013010] It was relatively safe and well tolerated and associated with some minor side effects (nausea, weakness, dizziness). Blood dyscrasias were not a problem associated with its use. A pharmacokinetics study on AQ for treatment of *P.vivax* in pregnancy conducted in Thailand indicates the doses are similar to that of non-pregnant adults.[@b131-mjhid-5-1-e2013010],[@b135-mjhid-5-1-e2013010]

There are fewer reports on the efficacy and safety of mefloquine (MQ) for MiP. High cure rates have been reported in Thailand, for the combination of MQ+AS (cure rate of 98.2% at day 63).[@b126-mjhid-5-1-e2013010] One study reported minor side effects.[@b109-mjhid-5-1-e2013010] However, there are concerns about still births and neuropsychiatric disorders. There are currently some ongoing clinical studies which will provide useful data on the safety, efficacy and pharmacokinetics of MQ in pregnant women ([Table 5](#t5-mjhid-5-1-e2013010){ref-type="table"}). The combination AS+ MQ is being evaluated in studies in Africa and Asia (NCT00852423, NCT00701961, NCT01054248, CTRI/2009/091/001055TEMP, NCT01054248).

In Uganda, in an area of relatively high transmission and hence with pregnant women having some acquired immunity, artemether-Lumefantrine (AL) was efficacious, with cure rates \>95%.[@b136-mjhid-5-1-e2013010]--[@b137-mjhid-5-1-e2013010] However, in Thailand the cure rate at day 42 was only 82%,[@b138-mjhid-5-1-e2013010] possibly due to the low day 7 lumefantrine concentrations. AL was safe and well tolerated.[@b136-mjhid-5-1-e2013010]--[@b138-mjhid-5-1-e2013010] As for other antimalarial treatments, pharmacokinetics may be altered during pregnancy, with plasma concentrations lower than expected.[@b129-mjhid-5-1-e2013010],[@b139-mjhid-5-1-e2013010] AL is currently being evaluated in Thailand and in four sites in sub-Saharan Africa (NCT01054248, NCT00852423).

Dihydroartemisinin piperaquine (DHAPQ) was highly effective in women with multiple recrudescent infections on the Thai-Burmese border.[@b140-mjhid-5-1-e2013010] DHAPQ is used in the Western Pacific for malaria in pregnant women.[@b141-mjhid-5-1-e2013010] DHA-PQ is currently being evaluated in 3 studies in Africa and Asia (NCT00852423, NCT01054248, NCT01231113). Cure rates and PK are reassuring.

In Thailand, atovaquone-proguanil in combination with artesunate (AAP) was associated with high cure rates (\>95%) and was relatively safe,[@b123-mjhid-5-1-e2013010],[@b142-mjhid-5-1-e2013010] though the sample size was small. In Thailand, plasma concentrations of AAP were lower in pregnant than in non pregnant women.[@b143-mjhid-5-1-e2013010]

Conclusions
-----------

This review shows that although the deleterious effects of MiP to both the mother and the child are well documented, the mechanisms involved are still relatively unknown, particularly where transmission is low and unstable. The diagnosis of MiP is challenging, as peripheral microscopy will miss a large proportion of infected women with parasites sequestered in the placenta. MiP can be prevented by currently available control methods, i.e. ITNs and IPTp, but the challenge is attaining a high coverage, particularly for women with the highest risk such as adolescent primigravidae. It is still unclear what would be the alternative to SP for the IPTp.

The burden of *P. vivax* MiP, which is substantial in the Asia-Pacific region and in South America has been relatively neglected. It is generally believed that vivax infections are milder than falciparum ones, but this is based on few studies. There is also the need of having more sensitive diagnostic methods for vivax infections, as it would help improving early diagnosis and appropriate management. Finally, information of the safety and efficacy of antimalarials during pregnancy is growing, though this is true mainly for the second and third trimester. For the first trimester, treatment options are still extremely limited and evidence is mainly based on pharmacovigilance data on accidental exposures.
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###### 

Burden of malaria in pregnancy in sub-Saharan Africa

  Country                                      Year         N          Parasite prevalence                                             Trimester                                                       Diagnosis   Species[\*](#tfn1-mjhid-5-1-e2013010){ref-type="table-fn"}   
  -------------------------------------------- ------------ ---------- --------------------------------------------------------------- --------------------------------------------------------------- ----------- ------------------------------------------------------------ -----------
  Burkina Faso \[[@b23-mjhid-5-1-e2013010]\]   2006--2008   1034       39.2[a](#tfn2-mjhid-5-1-e2013010){ref-type="table-fn"}                                                                          1--3        M                                                            F
  Nigeria \[[@b19-mjhid-5-1-e2013010]\]                     396        18 [b](#tfn3-mjhid-5-1-e2013010){ref-type="table-fn"}                                                                           2,3         M                                                            F
  Benin \[[@b30-mjhid-5-1-e2013010]\]          2008--2010   982                                                                        11.5[i](#tfn10-mjhid-5-1-e2013010){ref-type="table-fn"}         1--3        M, RDT, H                                                    
  Ghana \[[@b90-mjhid-5-1-e2013010]\]          2000         596                                                                        32, 38, 56 [c](#tfn4-mjhid-5-1-e2013010){ref-type="table-fn"}                                                                            F
  Ghana \[[@b27-mjhid-5-1-e2013010]\]          2009         363        28.40                                                                                                                           3           M                                                            
  Burkina \[[@b49-mjhid-5-1-e2013010]\]        1987--1988   1190       5--11[d](#tfn5-mjhid-5-1-e2013010){ref-type="table-fn"}         8.7                                                                                                                                      F \>90%
  Kenya \[[@b36-mjhid-5-1-e2013010]\]          1996--1997   912        10--24                                                          30--64[e](#tfn6-mjhid-5-1-e2013010){ref-type="table-fn"}        2,3         M, H                                                         
  Tanzania \[[@b144-mjhid-5-1-e2013010]\]      2003--2004   413                                                                        8%                                                              1,2                                                                      
  Cameroon \[[@b22-mjhid-5-1-e2013010]\]       1996--1998   278        22.6, [f](#tfn7-mjhid-5-1-e2013010){ref-type="table-fn"} 76.1   26.8, 52.9                                                                  M, PCR                                                       F, others
  Malawi \[[@b24-mjhid-5-1-e2013010]\]         2002--2003   1869       20.1                                                                                                                                        M                                                            
  The Gambia\[[@b54-mjhid-5-1-e2013010]\]      2002--2005   783                                                                        9.5                                                                         H                                                            
  Cameroon \[[@b71-mjhid-5-1-e2013010]\]       2002         175                                                                        25.4                                                                                                                                     
  Kenya \[[@b50-mjhid-5-1-e2013010]\]          2003         85                                                                         44--81                                                          1--3        H                                                            
  Nigeria\[[@b80-mjhid-5-1-e2013010]\]         2002         304                                                                        33.2                                                                        H                                                            
  Senegal \[[@b72-mjhid-5-1-e2013010]\]                     692                                                                        10[h](#tfn9-mjhid-5-1-e2013010){ref-type="table-fn"}                        RDT, M                                                       
  Cameroon \[[@b34-mjhid-5-1-e2013010]\]       1998--2000   1143                                                                       44.7                                                                        M                                                            
  Cameroon \[[@b51-mjhid-5-1-e2013010]\]       1999--2001   770        32.8                                                            33.7                                                                        M                                                            
  Malawi\[[@b12-mjhid-5-1-e2013010]\]          2003--2006   475        2.30                                                                                                                                        M                                                            
  Angola\[[@b145-mjhid-5-1-e2013010]\]         2008         679        10.9                                                                                                                            1--3        M                                                            F
  Burkina \[[@b29-mjhid-5-1-e2013010]\]        2003         295, 288   11.9, 32.2[j](#tfn11-mjhid-5-1-e2013010){ref-type="table-fn"}                                                                   1--3        M                                                            F
  Gabon \[[@b31-mjhid-5-1-e2013010]\]          1995--1996   311        57                                                                                                                                          M                                                            F

F=*Plasmodium falciparum*; M: Microscopy, H: Histology;

incidence in per thousand women months;

peripheral and placental;

microscopy, RDT and PCR respectively;

according to trimester;

based on histology (primigravidae-multigravidae);

microscopy, PCR;

peripheral and placental;

RDT;

80/696;

dry season, transmission season

###### 

Malaria burden in pregnancy in Asia-Pacific and South America

                                                                                                                       Parasite prevalence                                                                                                                            
  ----------------------------------------- ------------ ------------------------------------------------------------- ---------------------------------------------------------------- ------------------------------------------------------- ------- ------------- -------------
  Thailand \[[@b42-mjhid-5-1-e2013010]\]    1986--2010   17613                                                         5[\*](#tfn17-mjhid-5-1-e2013010){ref-type="table-fn"}                                                                    1       M             F, V
  India\[[@b20-mjhid-5-1-e2013010]\]        2006--2007   2386 [a](#tfn13-mjhid-5-1-e2013010){ref-type="table-fn"}718   1.8                                                              2.4                                                     2,3     M, RDT        F, V, mixed
  Peru\[[@b16-mjhid-5-1-e2013010]\]         2004--2005   1645--1652^b^                                                 8.1--6.6                                                                                                                         M             F, V
  Venezuela\[[@b40-mjhid-5-1-e2013010]\]    200--2002    12                                                                                                                                                                                                           V
  Thailand \[[@b81-mjhid-5-1-e2013010]\]    1995--2002   204                                                           96.0[f](#tfn18-mjhid-5-1-e2013010){ref-type="table-fn"}          6.9%                                                    1,2,3   M             F, V, mixed
  Brazil\[[@b146-mjhid-5-1-e2013010]\]      1997         195                                                           67.7 [c](#tfn14-mjhid-5-1-e2013010){ref-type="table-fn"}, 29.7                                                                                 F, V, mixed
  Thailand\[[@b39-mjhid-5-1-e2013010]\]     1993--1996   1459                                                          37                                                                                                                       1,2,3   M             F, V, mixed
  Indonesia\[[@b141-mjhid-5-1-e2013010]\]   2004--2010   4478                                                          19                                                                                                                       2,3     M             
  Colombia\[[@b17-mjhid-5-1-e2013010]\]                  84                                                                                                                             13[d](#tfn15-mjhid-5-1-e2013010){ref-type="table-fn"}           M, PCR, RDT   
  Ecuador\[[@b21-mjhid-5-1-e2013010]\]      2001                                                                       56.3                                                                                                                                           F
  Peru\[[@b73-mjhid-5-1-e2013010]\]         2004         193                                                           1 [e](#tfn16-mjhid-5-1-e2013010){ref-type="table-fn"} 6.6        0.53 5.17                                                       M, PCR        F, V

F=*Plasmodium falciparum*; V= *Plasmodium vivax*; M: Microscopy, H: Histology;

Antenatal clinics, delivery units;

vivax, falciparum-pregnant women were symptomatic (fever);

microscopy;

microscopy, PCR;

estimated from table;

estimated from data presented in paper (175/402)

###### 

Trials on Intermittent Preventive Treatment in pregnancy

  Country                                                                                             Year         Trial arms                                                  N      Findings
  --------------------------------------------------------------------------------------------------- ------------ ----------------------------------------------------------- ------ ------------------------------------------------------------------------------------------------------------------------------------------------------------
  Uganda\[[@b110-mjhid-5-1-e2013010]\]                                                                2004--2007   SP vs SP+ITN vs ITN+placebo                                 5775   No differences between treatment arms
  Mali\[[@b100-mjhid-5-1-e2013010]\]                                                                  2006--2008   SP 3 vs 2 doses                                             814    SP3 vs SP2: 50% reduction in placental parasitaemia, LBW, pre-term births
  Ghana\[[@b107-mjhid-5-1-e2013010]\]                                                                 2004--2007   SP, AQ, SP+AQ                                               3643   No difference peripheral parasitaemia, adverse events more frequent with AQ
  Benin\[[@b109-mjhid-5-1-e2013010]\]                                                                 2005--2008   MQ, SP                                                      1601   No difference in LBW, MQ more efficacious than SP in preventing malaria, MQ had more adverse events
  Burkina Faso \[[@b37-mjhid-5-1-e2013010]\] [\*\*](#tfn23-mjhid-5-1-e2013010){ref-type="table-fn"}   2004--2006   SP                                                          1441   SP2 vs SP0[c](#tfn21-mjhid-5-1-e2013010){ref-type="table-fn"} At delivery, 96% reduction placental infection, increase PCV, reduction LBW in primigravidae
  Benin\[[@b108-mjhid-5-1-e2013010]\]                                                                 2005--2006   CQ, SP                                                      1699   SP vs CQ decreased LBW by 50%, placental infection by 80%
  Mozambique\[[@b101-mjhid-5-1-e2013010]\]                                                            2003--2005   SP, PB[a](#tfn19-mjhid-5-1-e2013010){ref-type="table-fn"}   1030   No reduction of LBW, anaemia at delivery and placenta malaria; 40% reduction incidence of clinical malaria
  Mozambique[\*](#tfn22-mjhid-5-1-e2013010){ref-type="table-fn"}\[[@b57-mjhid-5-1-e2013010]\]         2003--2005   SP, PB[a](#tfn19-mjhid-5-1-e2013010){ref-type="table-fn"}   1030   PE 61.3% neonatal mortality
  Ghana\[[@b26-mjhid-5-1-e2013010]\]                                                                  2007--2008   IPTp-SP, IST                                                3333   No difference between study arms but increase in Hb after intervention
  Nigeria\[[@b102-mjhid-5-1-e2013010]\]                                                               2003--2005   SP, CQ                                                      352    PE against anaemia: 49.5 SP vs CQ
  Nigeria\[[@b103-mjhid-5-1-e2013010]\]                                                               2002         SP, CQ-P                                                    500    SP better than CQ-P
  Mozambique\[[@b104-mjhid-5-1-e2013010]\]                                                            2001--2002   SP vs??                                                     600    Parasite prevalence SP 6.3% vs 13.6%, 2.4 vs 13.3, high loss to follow-up

PB=placebo, SP=sulfadoxine-pyrimethamine, AQ=amodiaquine, CQ=chloroquine, P=pyrimethamine;

12--28 weeks;

SP2=2 doses of SP, SP0=no dose of SP;

maternal and birth outcomes up to 8 weeks have been reported in \[[@b101-mjhid-5-1-e2013010]\];

community trial;

PE=parasitological efficacy; IST: Intermittent Screening and Treatment

###### 

Treatment trials and clinical studies on malaria in pregnancy

  Country                                                                                       Year         Antimalarial                                                 N       Trimester   Findings
  --------------------------------------------------------------------------------------------- ------------ ------------------------------------------------------------ ------- ----------- -----------------------------------------------------------------------------------------------------------------------------------------------
  Uganda\[[@b136-mjhid-5-1-e2013010]\]                                                          2006--2009   Q, AL                                                        304     2,3         day 42 CR: AL 99.7% Q 97.6; Q group more adverse events
  Ghana\[[@b122-mjhid-5-1-e2013010]\]                                                           2003--2004   CQ, AQ, SP, AQ+SP                                            900     2,3         day 28 PF: CQ 14%, SP 11%, AQ 3%, AQ+ SP 0%.
  Tanzania\[[@b125-mjhid-5-1-e2013010]\]                                                        2004--2006   SP, CD, AQ+SP, AS+AQ                                         272     2,3         day 28 PF: CD 18%, AQ+SP 1%, AS+AQ 4.5%.
  Uganda\[[@b137-mjhid-5-1-e2013010]\]                                                          2006         AL, CD                                                       114     2,3         Day 28 CR: AL 100% CD 100%.
  Thailand\[[@b138-mjhid-5-1-e2013010]\]                                                        2004--2006   AL, AS7                                                      252     2,3         Day 42 or delivery CR: AS7 89.2%, AL 82%.
  Thailand\[[@b126-mjhid-5-1-e2013010]\]                                                        1995--1997   Q, AS+MQ                                                     108     2,3         Day 63 CR: AS+MQ 98.2%, Q 67%,
  Thailand\[[@b123-mjhid-5-1-e2013010]\]                                                        2001--2003   AAP, Q[\*](#tfn26-mjhid-5-1-e2013010){ref-type="table-fn"}   81      2,3         Day 63 CR: AAP 94.9%, Q 63.4%
  Thailand\[[@b142-mjhid-5-1-e2013010]\]                                                        1999--2001   AAP                                                          27                  Day 42 CR: 96%
  Malawi\[[@b127-mjhid-5-1-e2013010]\]                                                          2003--2004   SP, SP+AZ, SP+AS                                             141     2,3         PF: SP-AS[a](#tfn27-mjhid-5-1-e2013010){ref-type="table-fn"} 14.3%, 11.4%, 44.8 %, Recrudescence less frequent in SP-AS vs SP (HR 0.25)
  Thailand\[[@b124-mjhid-5-1-e2013010]\]                                                        1997--2000   QC7, AS7                                                     129     2,3         both had 100% day 42 CR
  Uganda[c](#tfn30-mjhid-5-1-e2013010){ref-type="table-fn"}\[[@b128-mjhid-5-1-e2013010]\]       2008         A, DHA                                                       21      2,3         PK concentrations A and DHA lower than non pregnant adults
  Thailand\[[@b135-mjhid-5-1-e2013010]\]                                                                     AQ                                                           27                  AQ reduced recurrent infections from 22.2 to 7.4% day 35 for *P.vivax*, PK PD no adjustments of dose required
  PNG \[[@b147-mjhid-5-1-e2013010]\]                                                            2006         CQ for IPTp                                                  30      2,3         Reduced plasma concentrations CQ and metabolite
  Mali, Mozambique, Sudan, Zambia\[[@b148-mjhid-5-1-e2013010]\]                                 \-           SP for IPTp                                                  97      2,3         PK Inconsistent changes in concentrations of S and P
  Thailand [b](#tfn29-mjhid-5-1-e2013010){ref-type="table-fn"} \[[@b129-mjhid-5-1-e2013010]\]   2004--2006   L in AL                                                      103                 PK: 40% low capillary concentrations
  Thailand\[[@b133-mjhid-5-1-e2013010]\]                                                        \-           DHA&PQ                                                       24                  PK: Reduced exposure DHA, unaltered exposure PQ
  Thailand\[[@b131-mjhid-5-1-e2013010]\]                                                        2007--2008   AQ                                                           24      2, 3        PK: Safe, similar pharmacokinetic properties with non pregnant
  Thailand\[[@b139-mjhid-5-1-e2013010]\]                                                        2004         AL                                                           13      2,3         PK: Reduced plasma concentrations of both A and L
  Thailand\[[@b134-mjhid-5-1-e2013010]\]                                                        2000--2001   DHA                                                          24      2,3         PK: DHA lower
  Thailand\[[@b118-mjhid-5-1-e2013010]\]                                                        1992--2000   AS, A, sometimes in combination with MQ, co-A, AQ-PG         461     1           cumulative artemisinin PF: 6.6%; retreatment: 21.7
  Thailand\[[@b149-mjhid-5-1-e2013010]\]                                                        1995--2000   Q-PF, CQ-PV                                                  300     1           safe but more tinnitus and maternal anaemia for Q
  Thailand\[[@b42-mjhid-5-1-e2013010]\] [‡](#tfn28-mjhid-5-1-e2013010){ref-type="table-fn"}     1986--2010   Q, CQ-PV, AS, MQ                                             17613   1           miscarriage risk asymptomatic malaria OR=2.7, symptomatic malaria OR=3.99; no significant effect of drug on miscarriage or malformation rates
  Zambia\[[@b119-mjhid-5-1-e2013010]\]                                                          2004--2008   AL, SP                                                       1001    1           perinatal mortality OR AL vs SP 0.84(0.45--1.53), no difference in maternal mortality, still birth, LBW; increase abortion rate AL

AS=artesunate, A=artemether, AQ=amodiaquine, AZ=Azithromycine, C=clindamycin, CD=chlorproguanil-dapsone, DHA=dihydroartemisinin, PQ=piperaquine, CQ=chloroquine, L=lumefantrine, MQ=mefloquine, Q=quinine, SP=sulfadoxine-pyrimethamine; PF=parasitological failure; CR=clearance/cure rate; PE=parasitological efficacy; PK=pharmacokinetics; PNG=Papua New Guinea;

supervised quinine for 7 days;

peripheral microscopy, placental microscopy and placental histology;

part of data in McGready 2001 \[[@b118-mjhid-5-1-e2013010]\], Mc Gready 2002 \[[@b149-mjhid-5-1-e2013010]\];

data from McGready 2008\[[@b138-mjhid-5-1-e2013010]\];

main trial Piola 2010\[[@b136-mjhid-5-1-e2013010]\]

###### 

Registered ongoing trials on malaria treatment in pregnant women

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                                                                                                               Country                               Registration ID            intervention
  ----------------------------------------------------------------------------------------------------------------------------------- ------------------------------------- -------------------------- ---------------------------------------------
  Effective and safe treatment for malaria in pregnancy in India: a randomised controlled trial                                       India                                 CTRI/2009/091/001055TEMP   AS+SP, AS+MQ

  Randomized trial of 3 artemisinin combination therapy for malaria in pregnancy (DMA)                                                Thailand                              NCT01054248                AS+MQ, AL, DHA+PQ

  Safe and efficacious artemisinin-based combination treatments for African pregnant women with malaria (PREGACT)                     Burkina Faso, Ghana, Malawi, Zambia   NCT00852423                DHA-PQ, AS+MQ, AS+AQ, AL

  Pharmacokinetics of mefloquine-artesunate in Plasmodium falciparum malaria infection in pregnancy                                   Burkina Faso                          NCT00701961                MQ-AS (pregnant vs. non- pregnant)

  ACT in pregnant women                                                                                                               Nigeria                               PACTR2010020001862624      Experimental group: AS/AQ, control group AL

  Efficacy, safety and tolerability of dihydroartemisinin- piperaquine for treatment of uncomplicated malaria in pregnancy in Ghana   Ghana                                 NCT01231113                Drug: AS-AQ\
                                                                                                                                                                                                       Drug: DHA-PQ fixed-dose combination
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
